Tigenix NV (TIG) Given Average Recommendation of “Strong Buy” by Analysts

Shares of Tigenix NV (NASDAQ:TIG) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus target price of $28.50 for the company, according to Zacks. Zacks has also given Tigenix an industry rank of 102 out of 265 based on the ratings given to its competitors.

A number of brokerages have recently issued reports on TIG. Canaccord Genuity restated a “buy” rating and issued a $30.00 target price on shares of Tigenix in a research note on Tuesday, October 31st. BidaskClub lowered shares of Tigenix from a “hold” rating to a “sell” rating in a research note on Friday, October 27th. Finally, Zacks Investment Research lowered shares of Tigenix from a “hold” rating to a “sell” rating in a research note on Saturday, October 21st.

Shares of Tigenix (TIG) traded up $0.33 during trading on Friday, hitting $22.50. 5,400 shares of the stock were exchanged, compared to its average volume of 9,633. The company has a current ratio of 1.37, a quick ratio of 1.36 and a debt-to-equity ratio of 0.10. Tigenix has a 1-year low of $10.77 and a 1-year high of $25.72.

A hedge fund recently bought a new stake in Tigenix stock. EAM Investors LLC purchased a new stake in Tigenix NV (NASDAQ:TIG) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 155,886 shares of the company’s stock, valued at approximately $3,517,000. EAM Investors LLC owned approximately 1.20% of Tigenix as of its most recent filing with the Securities and Exchange Commission. 5.31% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/tigenix-nv-tig-given-average-recommendation-of-strong-buy-by-analysts.html.

Tigenix Company Profile

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.

Get a free copy of the Zacks research report on Tigenix (TIG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tigenix NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tigenix NV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply